A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

Blood

Volumn 121, Issue 17, 2013, Pages 3420-3427

  Wechalekar, Ashutosh D ^a   Schonland, Stefan O ^b   Kastritis, Efstathios ^c   Gillmore, Julian D ^a   Dimopoulos, Meletios A ^c   Lane, Thirusha ^a   Foli, Andrea ^d   Foard, Darren ^a   Milani, Paolo ^d   Rannigan, Lisa ^a   Hegenbart, Ute ^b   Hawkins, Philip N ^a   Merlini, Giampaolo ^d   Palladini, Giovanni ^d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DEXAMETHASONE DERIVATIVE; LENALIDOMIDE; MELPHALAN; MELPHALAN DEXAMETHASONE; PREDNISONE; THALIDOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TROPONIN T;

ADULT; AGED; AL AMYLOIDOSIS; ARTICLE; CARDIAC PATIENT; FEMALE; GERMANY; GREECE; HEART AMYLOIDOSIS; HUMAN; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; ITALY; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; AMYLOIDOSIS; EUROPE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TROPONIN T;

MLCS; MLOWN;

EID: 84879458198     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-473066     Document Type: Article

References (32)

1. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924-1933.
2. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047-2060.
3. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003; 361(9371):1787-1789.
4. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440-2445.
5. Kristen AV, Giannitsis E, Lehrke S, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood. 2010; 116(14):2455-2461.
6. Wechalekar AD, Gillmore JD, Wassef N, Lachmann HJ, Whelan C, Hawkins PN. Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. Haematologica. 2011;96(7):1079-1080.
7. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757.
8. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104(6):1881-1887.
9. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-995.
10. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8):2936-2938.
11. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031-1037.
12. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012; 119(19):4387-4390.
13. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4394.
14. Schönland SO, Dreger P, de Witte T, Hegenbart U. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant. 2012;47(7):895-905.
15. Merlini G. CyBorD: stellar response rates in AL amyloidosis. Blood. 2012;119(19):4343-4345.
16. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426-3430.
17. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002; 346(23):1786-1791.
18. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457-464.
19. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492-496.
20. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465-470.
21. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79(4):319-328.
22. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
23. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520-2530.
24. Kyle RA, Gertz MA, Greipp PR, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999;93(3):1062-1066.
25. Wechalekar AD, Goodman HJB, Gillmore JD, et al. Efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis [abstract]. Blood. 2005;106(11):976A. Abstract 3496.
26. Jaccard A, Moreau P, Leblond V, et al; Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083-1093.
27. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865-873.
28. Palladini G, Russo P, Lavatelli F, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol. 2009;88(4):347-350.
29. Dietrich S, Schönland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood. 2010;116(4):522-528.
30. Madan S, Kumar SK, Dispenzieri A, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119(5):1117-1122.
31. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010; 468(7320):93-97.
32. Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011;118(25):6610-6617.